Kidney Fibrosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Kidney Fibrosis – Pipeline Review, H2 2016’, provides an overview of the Kidney Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis

The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Angion Biomedica Corp.


BiOrion Technologies B.V.

Cellmid Limited

Epigen Biosciences, Inc.

Evotec AG

Galectin Therapeutics, Inc.

GenKyoTex S.A.

Intercept Pharmaceuticals, Inc.

Isarna Therapeutics GmbH

Lpath, Inc.

MorphoSys AG

Pharmaxis Limited

ProMetic Life Sciences Inc.

Raptor Pharmaceutical Corp.

Regulus Therapeutics Inc.

Symic Biomedical, Inc.

Tobira Therapeutics, Inc.

Vascular Biogenics Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Kidney Fibrosis Overview 10

Therapeutics Development 11

Pipeline Products for Kidney Fibrosis - Overview 11

Pipeline Products for Kidney Fibrosis - Comparative Analysis 12

Kidney Fibrosis - Therapeutics under Development by Companies 13

Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 15

Kidney Fibrosis - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Kidney Fibrosis - Products under Development by Companies 18

Kidney Fibrosis - Products under Investigation by Universities/Institutes 20

Kidney Fibrosis - Companies Involved in Therapeutics Development 21

AbbVie Inc 21

Angion Biomedica Corp. 22

Bio-inRen 23

BiOrion Technologies B.V. 24

Cellmid Limited 25

Epigen Biosciences, Inc. 26

Evotec AG 27

Galectin Therapeutics, Inc. 28

GenKyoTex S.A. 29

Intercept Pharmaceuticals, Inc. 30

Isarna Therapeutics GmbH 31

Lpath, Inc. 32

MorphoSys AG 33

Pharmaxis Limited 34

ProMetic Life Sciences Inc. 35

Raptor Pharmaceutical Corp. 36

Regulus Therapeutics Inc. 37

Symic Biomedical, Inc. 38

Tobira Therapeutics, Inc. 39

Vascular Biogenics Ltd. 40

Kidney Fibrosis - Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 45

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

ANG-3070 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

ANG-3586 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ANG-4021 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

BOT-191 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

BRN-1889 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

CAB-102 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

cenicriviroc mesylate - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

CT-140 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

cysteamine DR - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Drugs for Tissue Fibrosis - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

GKT-136901 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

GRMD-02 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

ICG-001 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

INT-767 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

ISTH-0047 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

LJ-1888 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Lpathomab - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

melittin - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

MOR-107 - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

P-007 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

PBI-4050 - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

PBI-4419 - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

PXS-4820 - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

PXS-5033A - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

RG-012 - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

SB-300 - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

SOL-1 - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

VB-703 - Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

Kidney Fibrosis - Dormant Projects 122

Kidney Fibrosis - Product Development Milestones 123

Featured News & Press Releases 123

Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis 123

Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics 123

Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting 124

Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 125

Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 127

Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 127

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 128

Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 128

Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 129

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Tables

List of Tables

Number of Products under Development for Kidney Fibrosis, H2 2016 11

Number of Products under Development for Kidney Fibrosis – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2016 20

Kidney Fibrosis – Pipeline by AbbVie Inc, H2 2016 21

Kidney Fibrosis – Pipeline by Angion Biomedica Corp., H2 2016 22

Kidney Fibrosis – Pipeline by Bio-inRen, H2 2016 23

Kidney Fibrosis – Pipeline by BiOrion Technologies B.V., H2 2016 24

Kidney Fibrosis – Pipeline by Cellmid Limited, H2 2016 25

Kidney Fibrosis – Pipeline by Epigen Biosciences, Inc., H2 2016 26

Kidney Fibrosis – Pipeline by Evotec AG, H2 2016 27

Kidney Fibrosis – Pipeline by Galectin Therapeutics, Inc., H2 2016 28

Kidney Fibrosis – Pipeline by GenKyoTex S.A., H2 2016 29

Kidney Fibrosis – Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 30

Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH, H2 2016 31

Kidney Fibrosis – Pipeline by Lpath, Inc., H2 2016 32

Kidney Fibrosis – Pipeline by MorphoSys AG, H2 2016 33

Kidney Fibrosis – Pipeline by Pharmaxis Limited, H2 2016 34

Kidney Fibrosis – Pipeline by ProMetic Life Sciences Inc., H2 2016 35

Kidney Fibrosis – Pipeline by Raptor Pharmaceutical Corp., H2 2016 36

Kidney Fibrosis – Pipeline by Regulus Therapeutics Inc., H2 2016 37

Kidney Fibrosis – Pipeline by Symic Biomedical, Inc., H2 2016 38

Kidney Fibrosis – Pipeline by Tobira Therapeutics, Inc., H2 2016 39

Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd., H2 2016 40

Assessment by Monotherapy Products, H2 2016 41

Number of Products by Stage and Target, H2 2016 43

Number of Products by Stage and Mechanism of Action, H2 2016 46

Number of Products by Stage and Route of Administration, H2 2016 49

Number of Products by Stage and Molecule Type, H2 2016 51

Kidney Fibrosis – Dormant Projects, H2 2016 122

List of Figures

List of Figures

Number of Products under Development for Kidney Fibrosis, H2 2016 11

Number of Products under Development for Kidney Fibrosis – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 41

Number of Products by Top 10 Targets, H2 2016 42

Number of Products by Stage and Top 10 Targets, H2 2016 42

Number of Products by Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Routes of Administration, H2 2016 48

Number of Products by Stage and Routes of Administration, H2 2016 48

Number of Products by Molecule Types, H2 2016 50

Number of Products by Stage and Molecule Types, H2 2016 50


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports